Puma Biotechnology Inc(PBYI) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. The company was founded in 2010 and is headquartered in Los Angeles, California.

Current Price

$9.64

RSI

38.385

Beta:

1.303364

March 01, 2021
85.3M
98.3M
-15.7M

-16.473 %
2.411 %
-32.039 %
27.193 %

$225,110,000
$272,260,000
$250,991,000
$27,685,000
$0
$0
-20.945 %
8.474 %
806.596 %
0.000 %
0.000 %

$-59,788,000
$-75,595,000
$-113,575,000
$-291,955,000
$-276,011,000
$-239,284,000
26.438 %
50.241 %
157.059 %
-5.461 %
-13.306 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.